MD2-TLR4-IN-1

CAS No. 2249801-12-3

MD2-TLR4-IN-1( —— )

Catalog No. M20941 CAS No. 2249801-12-3

MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 260 Get Quote
10MG 410 Get Quote
25MG 678 Get Quote
50MG 954 Get Quote
100MG 1287 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MD2-TLR4-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex inhibitor.
  • Description
    MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    TLR
  • Recptor
    MD2-TLR4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2249801-12-3
  • Formula Weight
    421.28
  • Molecular Formula
    C22H14Cl2N4O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (197.80 mM)
  • SMILES
    O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhiguo Liu Lingfeng et al. Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury.[J]. Journal of medicinal chemistry 2019.
molnova catalog
related products
  • BMS-378806

    BMS-378806 selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.

  • CU-CPT17e

    CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).

  • Tomaralimab

    Tomaralimab (OPN-305) is a humanized IgG4 monoclonal antibody targeting TLR2, used to study myelodysplastic syndromes (MDS).